Information on Medicines and Healthcare products Regulatory Agency spending over £25,000.
Similar Posts
Manufacturer’s Online Reporting Environment (MORE)
A digital platform designed to facilitate the reporting, monitoring, and management of medical device incidents.
Field Safety Notices: 16-20 February 2026
List of Field Safety Notices: 16-20 February 2026
Improving Information Supplied with Gabapentinoids (Pregabalin/Gabapentin), Benzodiazepines and Z-Drugs
The MHRA has reviewed the warnings regarding addiction, dependence, withdrawal, and
tolerance for gabapentin, pregabalin, benzodiazepines, and z-drugs. The findings (detailed in the Public Assessment Report) were that it was necessary to strengthen these warnings in the product information and on packaging to better inform healthcare professionals and patients of these known risks.RegulatoryConnect
The Medicines and Healthcare Regulatory Agency have launched RegulatoryConnect, a service that provides the capability to track applications and view live authorisation details.
MHRA appoints first Chief Medical and Scientific Officer
Professor Jacob George has been appointed as the first Chief Medical and Scientific Officer for the Medicines and Healthcare products Regulatory Agency (MHRA).